“9 LIVES? I WISH!”

There’s no time to waste when a cat’s eating habits change, and they are losing weight.

Mirataz® (mirtazapine transdermal ointment) is the only FDA-approved transdermal medication for the management of weight loss in cats.

Mirataz® gives pet owners an option for one less oral medication for their cats. Oral administration of medication can be complicated in ill cats that are also anorexic, nauseated, or vomiting. Plus, generic mirtazapine tablets must be split or broken and have been shown to result in accidental overdose and toxicity.¹

Mirataz has a similar elimination half-life to oral mirtazapine but a lower maximum serum concentration, lower variation of drug concentration in blood plasma, and longer time at maximum serum concentration.³

References:
4 Data on file. REF-0272, Kindred Biosciences, Inc.

Mirataz® is a registered trademark of Kindred Biosciences, Inc. in the United States and/or other countries. © 2020 Kindred Biosciences, Inc., Burlingame, CA 94010. All rights reserved. US-MAZ-2000011 MAR-20

For more information about Mirataz, go to kindredbio.com/Mirataz.

Do not use Mirataz in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). See next page for additional important safety information.
Mirataz® (mirtazapine transdermal ointment) is indicated for the management of weight loss in cats.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For additional safety information, see brief summary of prescribing information on page XX.

Identifying weight loss early — and managing it long term — can help feline patients’ overall health.

Analyzing patient records of more than 2,600 cats showed lifespan decreased when cats had a body condition score (BCS) less than 5 out of 9.5

To improve patient outcomes, help cat owners understand time is of the essence.

Visit kindredbio.com/Mirataz or call 1-888-608-2542.